Research and Manufacturing company Materia Medica Holding is one of the major Russian pharmaceutical companies. It is the only Russian company manufacturing medicines of a new class based on ultra low doses of antibodies to endogenous regulators. Company's product portfolio includes OTC drugs of different pharmacological groups, such as immunomodulators, antiviral products, anti-inflammatory drugs, sedative drugs, nootropics, regulators of the urogenital system and reproductive system functions. The products are marketed in Russia and the CIS countries. For more than 10 years Materia Medica Holding has been carrying out fundamental research in the pharmacology of ultra low doses, and currently the company holds the leading position in this field. The staff of Materia Medica Holding exceeds 600 people. The company has its own production site in Chelyabinsk equipped with the up-to-date GMP-compliant facilities of European manufacturers. The efforts of the company’s staff for development and introduction into medical practice of new highly effective remedies based on ultra low doses of antibodies to endogenous regulators were recognized with Science & Technology Award 2005 and Science & Technology Award 2006 by Government of the Russian Federation (orders of the Government of the Russian Federation No. 96 dd. February 20th , 2006 AND No. 12 dd. February 22nd , 2007). We are trying to develop highly effective drugs able to solve the problems of treatment, prevention and rehabilitation in different medical areas. We believe that our products will help millions of people to be healthy.